Xintela AB (publ)
XINT
Rank in Stocks
#28124
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden,... Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
Share Price
$0.01428366
Last synced: 2026-11-09
Market Cap
$12.30M
Change (1 day)
3.13%
Change (1 year)
-48.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Xintela AB (publ) (XINT)
Category
Healthcare
Operating Margin for Xintela AB (publ) (XINT)
Operating Margin as of November 2026 TTM: -1,518.55%
According to Xintela AB (publ)'s latest financial reports, its current operating margin (TTM) is -1,518.55%. At the end of 2025 the company had an operating margin of -2,045.75%.
Operating Margin history for Xintela AB (publ) from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,518.55% | -25.77% |
| 2025 | -2,045.75% | 118.59% |
| 2024 | -935.87% | -98.72% |
| 2023 | -73,382.05% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -100,123.68% | 6,634.49% |
| 2018 | -1,486.73% | -99.86% |
| 2017 | -1,096,650.00% | 92.43% |
| 2016 | -569,900.00% | 37,368.77% |
| 2015 | -1,521.00% | -94.90% |
| 2014 | -29,852.11% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.03% |
US
|
|
| -149.01% | -99.90% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Xintela AB (publ)'s operating margin
What is Xintela AB (publ)'s operating margin?
Xintela AB (publ)'s operating margin is -1,518.55%, as of Nov 2026.
What was Xintela AB (publ)'s operating margin in 2025?
In 2025, Xintela AB (publ)'s operating margin was -2,045.75%, compared with -935.87% in 2024.
How has Xintela AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Xintela AB (publ)'s operating margin was highest in 2022 (0.00%) and lowest in 2023 (-73,382.05%).
How does Xintela AB (publ)'s operating margin compare with similar companies?
Xintela AB (publ)'s operating margin (-1,518.55%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.